<?xml version='1.0' encoding='utf-8'?>
<document id="21284263"><sentence text="Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions."><entity charOffset="28-55" id="DDI-PubMed.21284263.s1.e0" text="medroxyprogesterone acetate" /><entity charOffset="57-60" id="DDI-PubMed.21284263.s1.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.21284263.s1.e0" e2="DDI-PubMed.21284263.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21284263.s1.e0" e2="DDI-PubMed.21284263.s1.e1" /></sentence><sentence text="The aim of the present study was to investigate the inhibitory effects of medroxyprogesterone acetate (MPA) on four important UGT isoforms (UGT1A1, 1A6, 1A9 and 2B7)"><entity charOffset="74-101" id="DDI-PubMed.21284263.s2.e0" text="medroxyprogesterone acetate" /><entity charOffset="103-106" id="DDI-PubMed.21284263.s2.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.21284263.s2.e0" e2="DDI-PubMed.21284263.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21284263.s2.e0" e2="DDI-PubMed.21284263.s2.e1" /></sentence><sentence text=" 4-methylumbelliferone (4-MU) was used as a nonselective substrate, and recombinant UGT isoforms were utilized as an enzyme source"><entity charOffset="1-22" id="DDI-PubMed.21284263.s3.e0" text="4-methylumbelliferone" /><entity charOffset="24-28" id="DDI-PubMed.21284263.s3.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.21284263.s3.e0" e2="DDI-PubMed.21284263.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21284263.s3.e0" e2="DDI-PubMed.21284263.s3.e1" /></sentence><sentence text=" The results showed that MPA exhibited inhibitory effects on UGT2B7 (IC50 = 29"><entity charOffset="25-28" id="DDI-PubMed.21284263.s4.e0" text="MPA" /></sentence><sentence text="3 +/- 1" /><sentence text="5 microM), with a negligible influence on other UGT isoforms" /><sentence text=" The results obtained from Lineweaver-Burk and Dixon plots showed that MPA competitively inhibited UGT2B7"><entity charOffset="71-73" id="DDI-PubMed.21284263.s7.e0" text="MPA" /></sentence><sentence text=" The Ki value was calculated to be 7" /><sentence text="2 microM" /><sentence text=" Based on the concentration of MPA in human liver, the magnitude of in vivo drug-drug interaction (DDI) was predicted"><entity charOffset="31-33" id="DDI-PubMed.21284263.s10.e0" text="MPA" /></sentence><sentence text=" The [I]/Ki value was calculated to be 0" /><sentence text="31, which suggested that DDIs might occur when MPA was co-administered with drugs which mainly undergo UGT2B7-mediated metabolism"><entity charOffset="47-49" id="DDI-PubMed.21284263.s12.e0" text="MPA" /></sentence><sentence text="" /></document>